Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Nordics has been witnessing significant growth over the past few years, driven by various factors such as increasing prevalence of cardiovascular diseases and rising geriatric population.
Customer preferences: Patients in Nordics are highly aware of the benefits of anti-coagulants in preventing and treating blood clots. They prefer oral anti-coagulants over injectable ones due to ease of administration and convenience. Additionally, the preference for non-vitamin K antagonist oral anti-coagulants (NOACs) has been increasing due to their lower risk of bleeding and fewer dietary restrictions compared to traditional anti-coagulants.
Trends in the market: The anti-coagulants market in Nordics has been witnessing a shift towards NOACs, which are expected to replace traditional anti-coagulants in the near future. The market is also witnessing the emergence of biosimilars, which are expected to offer cost-effective treatment options to patients. Furthermore, the market is expected to witness significant growth due to the increasing prevalence of atrial fibrillation and deep vein thrombosis.
Local special circumstances: The healthcare systems in Nordics are highly advanced and offer universal coverage to all citizens. This has led to increased access to anti-coagulants among patients. Additionally, the presence of several pharmaceutical companies in the region has led to the availability of a wide range of anti-coagulants to patients.
Underlying macroeconomic factors: The aging population in Nordics has been driving the growth of the anti-coagulants market. According to the World Population Prospects 2019, the proportion of the population aged 65 years and above in Nordics is expected to increase from 19% in 2020 to 26% in 2050. This is expected to increase the burden of cardiovascular diseases, thereby driving the demand for anti-coagulants. Furthermore, the increasing healthcare expenditure and the presence of favorable reimbursement policies are expected to drive the growth of the anti-coagulants market in Nordics.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
